 CAMBRIDGE, Mass., March 11, 2021 GLOBE NEWSWIRE -- Foghorn Therapeutics Inc. Nasdaq: FHTX, a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that the company will present a poster and chair a panel at the American Association for Cancer Research AACR Annual Meeting 2021, which is being held virtually from April 10-15. 